Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant

References

• Sureda A, Arranz R, Iriondo A, . Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 2001;19:1395–1404.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Nimer SD, Zelenetz AD, . A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97:616–623.
   PubMed Web of Science ®Google Scholar
• Czyz J, Dziadziuszko R, Knopinska-Postuszuy W, . Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients. Ann Oncol 2004;15:1222–1230.
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Nimer SD, Zelenetz AD, . Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2003;32:673–679.
   PubMed Web of Science ®Google Scholar
• Paltiel O, Rubinstein C, Or R, . Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma. Bone Marrow Transplant 2003;31:565–569.
   PubMed Web of Science ®Google Scholar
• Popat U, Hosing C, Saliba RM, . Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant 2004;33:1015–1023.
   PubMed Web of Science ®Google Scholar
• Lavoie JC, Connors JM, Phillips GL, . High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005;106:1473–1478.
   PubMed Web of Science ®Google Scholar
• Sirohi B, Cunningham D, Powles R, . Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 2008;19:1312–1319.
   PubMed Web of Science ®Google Scholar
• Shamash J, Lee SM, Radford JA, . Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma: a two centre study. Ann Oncol 2000;11:715–719.
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Perales MA, Kewalramani T, . Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 2009;146:158–163.
   PubMed Web of Science ®Google Scholar
• Kaloyannidis P, Voutiadou G, Baltadakis I, . Outcomes of Hodgkin's lymphoma patients with relapse or progression following autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012;18:451–457.
   PubMed Web of Science ®Google Scholar
• Sureda A, Canals C, Arranz R, . Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante deMedula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012;97:310–317.
   PubMed Web of Science ®Google Scholar
• Thomson KJ, Peggs KS, Smith P, . Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 2008;41:765–770.
   PubMed Web of Science ®Google Scholar
• Sarina B, Castagna L, Farina L, . Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2012;115:3671–3677.
   Web of Science ®Google Scholar
• Smith SM, van Besien K, Carreras J, . Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant 2008;14:904–912.
   PubMed Web of Science ®Google Scholar
• Crump M. Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. Hematology Am Soc Hematol Educ Program 2008:326–333.
   Google Scholar
• van Haperen VW, Veerman G, Vermorken JB, . Regulation of phosphorylation of deoxycytidine and 2’,2’-difluorodeoxycytidine (gemcitabine); effects of cytidine 5’-triphosphate and uridine 5’-triphosphate in relation to chemosensitivity for 2’,2’-difluorodeoxycytidine. Biochem Pharmacol 1996;51:911–918.
   PubMed Web of Science ®Google Scholar
• Santoro A, Bredenfeld H, Devizzi L, . Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 2000;18:2615–2619.
   PubMed Web of Science ®Google Scholar
• Venkatesh H, Di Bella N, Flynn TP, . Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma. Clin Lymphoma 2004;5:110–115.
   PubMedGoogle Scholar
• Dougherty DW, Friedberg JW. Gemcitabine and other new cytotoxic drugs: will any find their way into primary therapy?Curr Hematol Malig Rep 2012;5:148–156.
   Google Scholar
• Cole PD, Schwartz CL, Drachtman RA, . Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a Children's Oncology Group report. J Clin Oncol 2009;27:1456–1461.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Niedzwiecki D, Johnson JL, . Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007;18:1071–1079.
   PubMed Web of Science ®Google Scholar
• Santoro A, Magagnoli M, Spina M, . Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 2007;92:35–41.
   PubMed Web of Science ®Google Scholar
• Chau I, Harries M, Cunningham D, . Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. Br J Haematol 2003;120:970–977.
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Nagy T, Pintilie M, . Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 2006;106:353–360.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Press OW, Shustov AR, . Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma 2010;51:1523–1529.
   PubMed Web of Science ®Google Scholar
• Ng M, Waters J, Cunningham D, . Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer 2005;92:1352–1357.
   PubMed Web of Science ®Google Scholar
• Ozkaynak MF, Jayabose S. Gemcitabine and vinorelbine as a salvage regimen for relapse in Hodgkin lymphoma after autologous hematopoietic stem cell transplantation. Pediatr Hematol Oncol 2004; 21:107–113.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
   PubMed Web of Science ®Google Scholar
• Oki Y, Pro B, Fayad LE, . Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 2008;112:831–836.
   PubMed Web of Science ®Google Scholar
• Horning S, Fanale M, deVos S, . Defining a population of Hodgkin Lymphoma patients for novel therapetics: an international effort. Ann Oncol 2008;19(Suppl. 4): Abstract 118.
   Google Scholar
• Martinez C, Canals C, Alessandrino D, . Relapse of Hodgkin's lymphoma (HL) after autologous stem cell transplantation (ASCT): prognostic factors in 462 patients registered in the database of the EBMT. J Clin Oncol 2010;28(Suppl. 15): Abstract 8060.
   PubMed Web of Science ®Google Scholar